Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icatibant - Takeda

Drug Profile

Icatibant - Takeda

Alternative Names: Firazyr; HOE-140; Icatibant; Icatibant acetate; JE-049; SHP-667

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Jerini; sanofi-aventis; Shire; Takeda
  • Class Analgesics; Antiallergics; Antiarrhythmics; Antifibrotics; Cardiovascular therapies; Kinins; Neuropeptides; Oligopeptides; Vascular disorder therapies
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Capillary leak syndrome; Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Preregistration Submission Withdrawal Angioedema
  • No development reported Capillary leak syndrome; Liver cirrhosis
  • Discontinued Arrhythmias; Musculoskeletal pain; Myocardial infarction; Pancreatitis; Rhinitis

Most Recent Events

  • 09 May 2019 Launched for Hereditary angioedema (In adults) in Japan (SC) (NCT04057131)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 21 Sep 2018 Efficacy and safety data from a phase III trial in Hereditary Angioedema in Japan released by Shire
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top